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Abstract
Background: Sarcoidosis is a systemic disease of unknown etiology that rarely occurs in children. 
It usually affects the lungs; however, it may involve various organs. It occasionally affects the 
general condition, and causes fever, hepatomegaly and splenomegaly.
Case report: We report the case of a twelve-year-old adolescent with late-onset childhood sar-
coidosis which diagnosis was confirmed by lymph node histopathological study. The patient 
presented general condition, hypercalcemia, erythema nodosum, severe lung disorders, lym-
phadenopathy, hepatomegaly and testicular mass. He received treatment with steroids, with 
excellent clinical response.
Conclusions: We highlight the importance of considering the diagnosis of sarcoidosis in patients 
with hepatomegaly, lymphadenopathy, diffuse lung damage, erythema nodosum, testicular 
mass and hypercalcemia, as well as the need for a multidisciplinary approach to assess multiple 
organ involvement and the early beginning of steroid treatment in order to prevent the progres-
sion of the disease.
© 2016 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A.This 
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1. Introduction
Sarcoidosis is a chronic systemic disease of unknown etiol-
ogy and worldwide distribution which is usually diagnosed 
in adults. Sarcoidosis in childhood is very rare.
Lungs are the most frequently affected organs; howev-
er, the disease can involve other organs such as eyes, skin, 
lymph nodes and joints. Less often it involves the nervous 
system, heart and urogenital tract, causing nephrolithiasis 
and a testicular mass; in some cases, fever of unknown 
origin with splenomegaly and hepatomegaly are observed.
The diagnosis of sarcoidosis is made by exclusion of oth-
er diseases. Therefore, once there is clinical suspicion, a 
biopsy of the organs involved shows, as a characteristic 
histopathological finding, the presence of noncaseating 
epithelioid granulomas.1
The first descriptions of sarcoidosis were made in Eu-
rope in the late nineteenth century. In 1877, in England, J. 
Hutchinson studied a patient with chronic skin lesions, ar-
thritis and chronic renal failure, and named the skin find-
ings papillary psoriasis. In France, in 1889, E. Besnier also 
described the skin lesions and named them lupus pernio. 
In 1899, in Denmark, C. Boeck labeled the skin histological 
lesions with the term sarkoid because of its similarity with 
sarcoma. In 1914, in Sweden, N. J. Schaumann described 
the systemic presentation of the disease; likewise, he 
pointed out that both Besnier s´ lupus pernio and Boeck s´ 
sarkoid were manifestations of the same disease, as the 
tissues affected in these patients showed granulomas 
which he called benign lymphogranulomatosis to differen-
tiate them from Hodgkin´ s malignant granuloma. The neu-
rologic involvement in sarcoidosis was reported by C. 
Heerfordt in 1923 who described patients with uveo-pa-
rotid fever and lesion of cranial nerves.
The acute pulmonary form of sarcoidosis accompanied 
of mediastinal lymphadenopathy and erythema nodosum, 
arthritis and uveitis was described in Sweden in 1953 by 
S. Löfgren.
For more than 130 years, most of the studies on sar-
coidosis have been performed in adults. However, pediat-
ric cases have been reported since 1923. The condition 
was known as Besnier-Boeck-Schaumann disease until 1958 
when the Sarcoidosis World Congress was carried out in 
London and the term sarcoidosis was generalized.2,3
Nowadays, accordingly to the international consensus 
established by the American Thoracic Society, the Euro-
pean Respiratory Society and the World Association for 
Sarcoidosis and Other Granulomatosis, sarcoidosis is con-
sidered to be a systemic granulomatous disease of un-
known etiology, which usually affects adults, and is very 
rare in children.4,5
The incidence and severity of sarcoidosis vary in differ-
ent regions of the world and in different ethnic groups 
probably due to variations in environmental exposures, 
the prevalence of HLA alleles and other genetic factors. 
Scandinavia, England, the United States and Japan have 
the highest prevalence of the disease; in Sweden, the 
morbidity rate in the general population is 64/100,000 and 
in the United States, 35/100,000.
There are very few epidemiological data on children. 
The rate of morbidity of childhood sarcoidosis is 
0.29/100,000; however, this rate varies from 0.06/100,000 
in children under 4 years to up to 1.02/100,000 in adoles-
cents aged 14 to 15 years.6-8
Regarding mortality from sarcoidosis, during the period 
1999-2010 the National Center for Health Statistics report-
ed sarcoidosis as a cause of death in 10,348 of 29,176,040 
deaths which represents a rate of 2.8/1,000,000 inhabit-
ants. However, mortality in the African-American popula-
tion was 12 times higher than in Caucasian population.9
In Mexico, the incidence of sarcoidosis is low, probably 
due to genetic factors or underreporting of cases. There-
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Resumen
Introducción. La sarcoidosis es una enfermedad sistémica de etiología desconocida que rara-
mente se presenta en la infancia. Generalmente afecta los pulmones; sin embargo, puede invo-
lucrar diversos órganos. Ocasionalmente afecta el estado general, y origina fiebre, hepatome-
galia y esplenomegalia.
Caso clínico. Se presenta el caso de un adolescente de doce años de edad con sarcoidosis infan-
til de inicio tardío, cuyo diagnóstico fue confirmado con un estudio histopatológico de ganglio 
linfático. El paciente cursó con afección general, hipercalcemia, eritema nodoso, alteraciones 
pulmonares graves, adenopatías, hepatomegalia y masa testicular. Recibió tratamiento con es-
teroides, con excelente respuesta clínica.
Conclusiones. Se resalta la importancia de considerar el diagnóstico de sarcoidosis en los pa-
cientes con hepatomegalia, adenopatías, daño pulmonar difuso, eritema nodoso, masa testicu-
lar e hipercalcemia, así como la necesidad del abordaje multidisciplinario para valorar el com-
promiso orgánico múltiple y el inicio oportuno de la terapia con esteroides, con el fin de evitar 
la progresión de la enfermedad.
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fore, there are no studies on the epidemiology of child-
hood sarcoidosis since only thirteen cases have been 
published in the last 20 years, including the case of a 
teenager with lung disease published by the National Insti-
tute of Respiratory Diseases and another report from the 
National Institute of Pediatrics about two cases of early-
onset cutaneous sarcoidosis.10-12
Sarcoidosis is a chronic inflammatory disease that re-
sults from the action of an environmental agent that trig-
gers an initial immune response of T-helper cells type 
1(Th1) and leads to the development of noncaseating gran-
ulomas with systemic involvement in genetically suscepti-
ble individuals.
According to epidemiological findings of the multicenter 
ACCESS (A Case Control Etiologic Study of Sarcoidosis), 
some environmental conditions are associated with an in-
creased risk for developing sarcoidosis, generating anti-
genic stimuli, which act as a trigger of the process. Some 
of the environmental conditions studied are organic mate-
rials (ragweed, pine leaves and seeds), inorganic materials 
(silica, beryllium, zirconium, titanium, aluminum and 
fiberglass) and microorganisms (Mycobacterium tuberculo-
sis, Propionibacterium acnes, Brucella, Borrelia, Leptospi-
ra, Mycoplasma, Leishmania and Schistosoma).
Although an infectious agent has not been conclusively 
identified (by culture or by ribosomal RNA markers in tis-
sue from biopsies), the hypothesis of a microbiological 
agent is the most accepted because there is clinical and 
epidemiological evidence of transmissibility of sarcoidosis. 
This observation comes from transplant patients who have 
developed the disease after tissue or organ transplantation 
from donors with sarcoidosis. Besides, it has been reported 
the development of sarcoidosis in the transplanted lung of 
a patient suffering from the disease; moreover, animals im-
planted with tissue from affected patients develop granu-
lomas.13-18
The existence of a predisposing genetic factor explains 
the higher incidence of the disease in relatives of patients 
with sarcoidosis, as well as differences in the prevalence 
and clinical course of the disease in different ethnic 
groups.
Recent research with molecular biology techniques has 
shown that genetic alterations associated with sarcoidosis 
are located in the major histocompatibility complex 
(MHC), on the short arm of chromosome 6, in histocom-
patibility antigens HLA I, such as HLA-B7 and HLA-B8, as 
well as in alleles of HLA class II such as HLA-DR5, HLA-
DR6, HLA-DR8 and HLA-DR9, which are related to high risk 
in Asian population. Likewise, genetic alterations are 
found in HLA -DRB1 in the African American population. 
In European population, HLA-DR14 and HLA-DR15 are re-
lated to chronic sarcoidosis, HLA-DR3 with the acute 
form, and HLA-DR17 with self-limited presentations of 
sarcoidosis.
The immune mechanisms that cause sarcoidosis are not 
completely known but it is assumed that macrophages do 
not adequately recognize and present antigens to T lym-
phocytes. However, patients with sarcoidosis do not have 
other evident manifestation of a cellular or humoral immu-
nodeficiency.
The process begins when the antigen phagocyted by 
the macrophage and the dendritic cell are presented on 
the MHC site. This enables the T cell to locate and bind to 
the MHC-II complex, and consequently to be activated and 
have clonal expansion, demonstrated by the increase in T 
cell receptor (TCR) mRNA, and by the presence of markers 
of antigen-specific T cell activation, such as CD69, glyco-
protein 240 and the very late antigen-1 (VLA-1).
Afterwards, T-CD4 lymphocytes differentiate to a Th-
1phenotype, and release cytokines such as interferon-γ 
(IFN-γ), tumor necrosis factor-α (TNF-α), transforming 
growth factor-β (TGF-β), IL-1β, IL-2, IL-12, IL-15 and IL-18, 
as well as several chemokines such as macrophage inflam-
matory protein 3α (MIP3α), interferon-inducible protein-10 
(IP-10), monocyte chemotactic protein-1 (MCP-1) and CCL5 
or RANTES (regulated on activation, normal T cell ex-
pressed and secreted). These chemokines maintain cell 
recruitment at sites of granuloma formation by their 
chemotactic effect.
T-regulatory cells from patients with chronic active sar-
coidosis have altered function which leads to the persis-
tence of inflammatory process and progression of 
granulomas. By contrast, patients with Löfgren syndrome, 
which is a form of acute sarcoidosis with a high rate of 
remission, have increased T-regulatory cells which reduce 
lymphocyte proliferation and cytokine production.
In some patients, the initial Th1-type response is re-
placed by a predominantly T-helper cell type 2 (Th2) re-
sponse, characterized by a decrease in IFN-γ, persistence 
of TNF-αand TGF-β activities, production of angiotensin 
converting enzyme (ACE), neopterin and IL-8. These pro-
teins reduce the formation of granulomas but, on the oth-
er hand, lead to the development of fibrosis due to the 
activity of some macrophage cytokines, like type1-insulin 
growth factor (IGF-1), platelet growth factor, IL-4 and IL-13 
which generate fibroblast activation and collagen and fi-
bronectin deposition in the extracellular space. The cause 
of progression to this fibro-proliferative form is unclear, 
but it may involve the loss of apoptotic mechanisms, loss 
of regulatory response, or persistence of an antigen that 
cannot be recognized or properly processed, which causes 
fibrous scarring and repair of the affected tissue with 
chronic and irreversible damage.19-24
Vitamin D deficiency has been shown to lead to an in-
creased risk of sarcoidosis, as the antigen presenting cells 
(macrophages, monocytes and dendritic cells) have vita-
min D receptors. This vitamin inhibits macrophage activa-
tion induced by IFN-γ and decreases the macrophage MHC 
II antigen presenting activity; so, it is supposed that this 
deficiency leads to altered regulation of Th1 cells, allow-
ing a persistent immune response.25-27
Furthermore, it has been found that activated mac-
rophages are capable of producing active vitamin D3 (cal-
citriol or 1,25-dihydroxycholecalciferol) and parathyroid 
hormone related peptide (PTHrP), which could contribute 
to hypercalcemia and hypercalciuria frequently present in 
this condition.28,29
One of the most remarkable findings in sarcoidosis is an 
immunological paradox. This paradox is characterized by 
intense cellular immune response in the affected organs in 
contrast to a situation of peripheral immunological aner-
gy, observed as a lack of response to PPD and other intra-
dermal tests. The likely explanation for this phenomenon 
is the presence of lymphopenia in peripheral blood, and 
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especially to the activity of suppressor T CD8+ lympho-
cytes.
Another phenomenon which is also subject of interest 
and controversy is the formation of granulomas in the skin 
of patients with sarcoidosis four to six weeks after the ap-
plication of sarcoid tissue extract in the Kveim-Siltz-
bachtest (used in the past for diagnostic purpose).30,31
The histological finding characteristic of sarcoidosis is 
the presence of noncaseating epithelioid granulomas dif-
fusely scattered in different tissues that mainly affect 
lymph nodes.
The granulomas of sarcoidosis have compact appear-
ance with well-defined borders. They may be at different 
stages of development, ranging from highly cellular granu-
lomas to structures of decreased cellularity with fibrosis 
or progressive hyalinization; besides, they do not have 
central necrosis neither foreign bodies, in contrast to 
granulomas caused by mycobacterial and fungal infec-
tions, or infestations by systemic metazoans.
The typical sarcoidosis granuloma has two characteris-
tic zones described below:
1.  The central zone or follicle is a dense cluster of epithe-
lioid cells, accompanied by lymphocytes, macrophages, 
Langhans multinucleated giant cells, mast cells and fi-
broblasts. In 60% of the cases, star shaped structures 
(asteroid bodies) and lamellar PAS+ structures of 1-15 
microns in diameter called Schaumann bodies can be 
observed. Immunohistochemical staining shows that 
the central zone of an active granuloma has mac-
rophages in various stages of activation and differen-
tiation. This zone is surrounded by CD4+ T cells 
intercalated with a small number of CD8+ T cells and B 
cells.
2.  The peripheral zone is formed by a ring of lympho-
cytes, monocytes and fibroblasts. T-regulatory CD3+/
CD4+/CD25+/Foxp3+ cells accumulate in this outer zone 
in addition to CD8+ T cells and fibroblasts, which leads 
to fibrosis when granulomas activity decreases.
In the chronic form of the disease, granulomas may be 
encapsulated by a fibrous halo or may be replaced by scars 
of fibrous and hyaline tissue.32-34
The clinical presentation of sarcoidosis in children var-
ies as it depends on the extent of the disease and the or-
gans involved. In most cases of childhood sarcoidosis, 
multiple organs are affected with a diffuse inflammatory 
reaction that causes systemic symptoms such as fever, fa-
tigue, hyporexia, nausea and weight loss, in addition to 
the specific signs and symptoms arising from dysfunction 
of each affected organ.
Sarcoidosis in childhood can occur in two clinical forms:
1.  Early onset sarcoidosis or Blau syndrome: It occurs be-
fore age five sporadically or in a familiar cluster. It is 
associated with NOD2/CARD15 gene located on chro-
mosome 16. In 75 % percent, the cases present a clini-
cal triad characterized by polyarthritis, uveitis and 
rash, whereas the remaining 25% are accompanied by 
other organs signs.
2.  Late onset sarcoidosis: It develops in children older 
than 5 years and resembles the adult clinical form. It is 
not associated with mutations in the NOD2/CARD15 
gene and it is characterized by fever, multiorgan in-
volvement, especially lung, skin, nervous system, eyes, 
kidneys, joints, lymph nodes, liver and spleen.35-36
The lung is involved in over 90% of cases; however, the 
clinical spectrum of the disease is wide. Most cases occur 
in an acute form, with malaise and non-specific respirato-
ry symptoms such as dry cough, dyspnea and airway hy-
perresponsiveness, but the disease can start insidiously 
and with minimal symptoms. The condition is mainly lo-
cated in the pulmonary interstitium, with enlarged hilar, 
tracheobronchial and mediastinal lymph nodes.
Approximately 70% of cases resolve spontaneously, but 
the remaining 30% evolves to chronicity and cause irre-
versible changes in lung parenchyma with fibrosis and for-
mation of pneumatoceles that lead to chronic respiratory 
failure and death.
Spirometry and plethysmography show a restrictive 
pattern, coincident with pulmonary dysfunction, and are 
useful to assess disease progression and response to treat-
ment.
Sarcoidosis may be stratified in four radiographic stag-
es, which guide the clinician to choose the treatment plan 
and to make a prognosis. In addition, radiographic imaging 
allows the follow up of the disease; the probability of re-
mission decreases according to the stage of evolution of 
the lesions. This is, while radiographic resolution in the 
first three stages of the disease is feasible, during stage 
IV, which is considered the end stage, radiographic lesions 
are already irreversible37 (Table 1).
The incidence of ocular involvement varies from 30 to 
70%. The characteristic lesion is uveitis. However, conjunc-
tiva, sclera, crystalline and lacrimal glands may also be af-
fected, resulting in cataract, glaucoma and dry 
keratoconjunctivitis. In the posterior segment patients may 
develop vitritis, ischemic retinal vasculitis with neovascu-
larization, occlusion of the central retinal vein, optic nerve 
affection, macular edema, perforating lesions, “wax drops” 
exudates and retinal detachment with blindness, which can 
be detected by slit lamp eye examination and retinangiog-
raphy.38,39
Skin disorders occur in 20 to 30% of the patients. The 
most frequent lesion is erythema nodosum, used as a 
marker of acute sarcoidosis since it usually disappears in 
6-8 weeks. The simultaneous appearance of erythema no-
dosum, fever, joint pain and hilar lymphadenopathy is 
Table 1 Chest radiographic staging*
Stages Findings Remission
Stage 0 Normal chest radiograph > 90%
Stage I Bilateral hilar lymphadenopathy 
(BHL)
60-90%
Stage II BHL plus pulmonary infiltrations 40-60%
Stage III Pulmonary infiltrations without 
BHL
10-20%
Stage IV Pulmonary fibrosis 0%
*Adaptation from The American Thoracic Society Statement on 
Sarcoidosis (ref. 4).
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called Löfgren syndrome. Other skin lesions include subcu-
taneous nodules, psoriasis like plaques, alopecia, hyper-
pigmented lesions and leukocytoclastic vasculitis.
Joint involvement is present in 80% of cases. It can be 
in the form of migratory polyarthritis and/or persistent ar-
thritis, as well as granulomatous tenosynovitis. When pol-
yarthritis, rash and uveitis occur in children under 5 years, 
it is recognized as Blau syndrome.40
Nervous system involvement occurs in 10% of patients, 
usually with involvement of II and VII cranial nerves as a 
result of granulomatous meningitis. However, CNS involve-
ment is found in up to 25% of autopsy cases of sarcoidosis.
Cardiac involvement is diagnosed clinically in less than 
5% of patients with sarcoidosis, although it has been found 
that 20 to 30% of post-mortem studies have lesions in the 
conduction system, which can cause arrhythmias and sud-
den death. Echocardiographic findings include ventricular 
dysfunction and decreased ejection fraction of the left 
ventricle; however, histological evidence of myocardial bi-
opsies requires cardiac catheterization.
Exocrine glands are frequently affected. Sarcoidosis 
can involve parotid and minor salivary glands in up to 60% 
of cases; granulomatous pancreatitis has also been re-
ported.
Renal involvement occurs in 10% of patients due to hy-
percalcemia, nephrocalcinosis and nephrolithiasis.
Clinical genitourinary involvement has been reported in 
0.2% of cases, and in 5% of autopsy studies, the most fre-
quent alteration being scrotal mass.41-48.
The diagnosis of childhood sarcoidosis is performed 
with the same criteria established for adults, published by 
the American Thoracic Society and the European Respira-
tory Society in 1999:
1.  Compatible clinical scenario.
2.  Histological evidence of noncaseating granulomas in 
biopsies obtained from the affected organs.
3.  Exclusion of other pathological processes that may pre-
sent with a similar clinical or histopathological presen-
tation, especially mycobacterial and fungal infections 
and other immunological processes.
There is no definitive test available to confirm the diag-
nosis of sarcoidosis. However, auxiliary studies are:
1.  Cytological analysis of bronchoalveolar lavage of pa-
tients with sarcoidosis shows a predominant lympho-
cyte cellularity in > 90% of cases. Furthermore, a CD4/
CD8 ratio > 3.5 by flow cytometry, has sensitivity of 
52-59% and specificity of 94-96% for the diagnosis of 
sarcoidosis.49-51
2.  Kveim-Siltzbach test has been used for sarcoidosis diag-
nosis since 1941. It consists of an intradermal inocula-
tion of a suspension obtained from spleen tissue of 
patients with sarcoidosis; a skin biopsy should be per-
formed 6 weeks after inoculation in search of granulo-
mas. The test has sensitivity of 75% and specificity 
> 90%, but currently its clinical application is restricted 
because of the difficulty in obtaining the reagent; be-
sides, it requires that the patient has not received ster-
oids, and some authors have discouraged it because of 
the risk of transmission of infectious diseases.51,52
3.  Serum angiotensin converting enzyme (ACE) quantifica-
tion has been used in the diagnosis of the disease, be-
cause 80% of pediatric patients with sarcoidosis have 
elevated ACE. It is also useful as a marker of disease 
activity as the enzyme levels descend when patients 
are in remission.
4.  Measurement of soluble receptor of interleukin-2 (sIL-
2R) is a test that has been very useful in evaluating the 
activity of the sarcoidosis.53-55
5.  Serum and urinary calcium are both useful in the diag-
nosis and monitoring of disease progression, as hyper-
calcemia occurs in 20% of cases and hypercalciuria in 
up to 60% and depend on the activity and the extent of 
the disease.56-60
2. Clinical case
We present the case of a twelve-year-old male with no 
relevant family history, parents and four siblings healthy. 
He was the product of a first pregnancy, born at term by 
vaginal delivery without perinatal complications. He had 
achieved age-appropriate psychomotor development and 
had a complete immunization schedule. He had no medi-
cal history except for chickenpox at the age of 6 years 
without complications.
Symptomatic disease began one year earlier with his 
first visit to the hospital, presenting dry cough in isolat-
ed bouts. During the last 6 months he had loss 12 kg of 
weight, and had asthenia, hyporexia, paleness, nausea 
and occasional vomiting of gastric content. Four months 
earlier, a mass growing in the left supraclavicular region 
and painless subcutaneous nodules appeared on both 
forearms. A week before admission he attended a region-
al hospital because of abdominal colic pain in the right 
flank and tenderness to lumbar percussion. Abdominal 
ultrasound showed hepatomegaly and right nephrolithia-
sis, so he was referred to our institution.
On physical examination, the pacient was conscious 
and well oriented, emaciated, pale, with equal sized pu-
pils reactive to light, without abnormal findings in ear, 
nose or throat. Cranial nerves function was preserved. 
The neck showed no jugular engorgement; he had cervi-
cal nodes of 0.5 to 1 cm, and a 2 cm mobile, painless 
node was present in the left supraclavicular zone which 
had no erythema or temperature increase. He had 
tachypnea and light intercostal retraction, respiratory 
movements were normal and breath sounds were normal 
without rales or wheezing. Heart sounds were rhythmic 
and without murmurs. The abdomen was soft. Hepatic 
border was 6 cm and spleen border 4 cm below the costal 
edge, bowel sounds were normal. He had Tanner II geni-
tal development stage and an asymmetric scrotum. Left 
testicle had a painless increase of volume with no transil-
lumination. Extremities were hypotrophic with erythema 
nodosum located in forearms and legs, had symmetrical 
peripheral pulses, normal tendon reflexes with no py-
ramidal signs.
Initial laboratory test results were: hemoglobin 14.4 g/
dl, leukocytes 7,600/mm3, neutrophils 48%, band forms 
4%, lymphocytes 37%, monocytes 7% platelets 286,000/
mm3, erythrocyte sedimentation rate 38 mm/h. C-reactive 
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protein <0.319 mg/dl. Blood chemistry showed glucose 91 
mg/dl, creatinine 1.5 mg/dl, BUN 17 mg/dl, uric acid 6 mg/
dl, serum proteins 8.6 g/dl, albumin 3.2 g/dl, globulins 5.4 
g/dl, total bilirubin 0.36 mg/dl, direct bilirubin 0.9 mg/dl, 
indirect bilirubin 0.27 mg/dl, ALT 35 U, AST 26 U, choles-
terol 120 mg/dl, triglycerides 160 mg/dl, Na 129 mmol/l, K 
3.6 mmol/l, Cl 98 mmol/l, Ca 13 mg/dl, P 4.02 mg/dl, Mg 
2.4 mg/dl, serum osmolality 268 mOsm/l. ABG without 
oxygen: pH 7.43, pCO2 32.4 mmHg, pO249.9 mmHg, HCO3 
21.3 mmol/l, SO2 83%, lactate 2.4 mmol/l, anion Gap 13.6 
mmol/l, TP 12.4'', TTP 29.3''.
Serologic studies for hepatitis A, B and C, CMV, EBV, 
varicella zoster, and type I and II herpes simplex virus 
were negative. ELISA for HIV was negative. Anti-ds-DNA 
antibodies, antinuclear antibodies (ANA), anti-neutrophil-
cytoplasmic antibodies (p-ANCA and c-ANCA) and VDRL 
were negative.
The urinalysis reported a density of 1.020, pH 6.0, 
abundant erythrocytes, leukocytes 1-2/field, negative ni-
trites, protein 75 mg/dl, sediment with calcium oxalate 
crystals and amorphous phosphate.
Twenty four-hour urine collection showed a creatinine 
clearance of 70.4 mg/ml/min, calciuria of 10.9 mg/kg/day, 
phosphaturia of 63.1 mg/kg/day. Tubular phosphate reab-
sorption was 63.3%, phosphorus/creatinine ratio (P/cr) 
0.80 mg/mg and calcium/creatinine ratio (Ca/cr) was 0.52 
mg/mg. Twenty four-hour oxaluria was 53.7 mg (<38 mg) 
and 24-h citric acid urine excretion, 427 mg (100-1300 mg).
Serum cystatin C, 2.18 mg/l (0.53-0.95 mg/l), parathy-
roid hormone (PTH), <1.20 pg/ml (10-55 pg/ml), calcitriol 
(1, 25-dihydroxy-vitamin D), 30.7 pg/ml (19.9-79.3 pg/ml), 
angiotensin converting enzyme (ACE), 272 U/l (13-100 U/l). 
Alpha-fetoprotein, 1.07 ng/ml (<10 ng/ml), human chori-
onic gonadotropin, 1.20 mIU/ml (<5 mIU/l).
PPD test with candidin control was negative. BAAR 
search in three samples of gastric juice was negative.
Bone marrow aspirate showed decreased cellularity, di-
minished megakaryocytes, metamyelocytes 2.5%, band 
forms 10.5%, mature neutrophils 35%, eosinophils 3%, lym-
phocytes 23.5%, blasts 1.5%, and normoblasts 24%.
Serum immunoglobulins: IgA 724 mg/dl (108-325 mg/dl), 
IgE 82.6 mg/dl (0-100 mg/dl), IgM 175 mg/dl (70-150 mg/
dl), IgG 2710 mg/dl (770-1510 mg/dl).
Complement: C3 113 mg/dl (90-180 mg/dl), C4 16.6 mg/
dl (10-40 mg/dl).
Nitroblue tetrazolium slide test and chemiluminescence 
at rest and after stimulus were normal. Soluble Interleu-
kin-2 receptor (sIL-2R), 3230 U/ml (406 -1100 U/ml).
Flow cytometry showed a normal quantity of T and B 
lymphocytes with a CD4/CD8 ratio of 1.22 (Table 2).
The initial chest X-ray showed diffuse reticular and mi-
cronodular infiltrates with bilateral hilar lymphadenopa-
thy (Figure 1).
X-rays showed normal skull, and long bones with evi-
dence of decalcification (Figure 2).
Thoracoabdominal computed tomography showed lymph 
node clusters in the mediastinum, mesentery, retroperito-
neal and inguinal regions, bilateral diffuse micronodular 
infiltration of the lungs, hepatomegaly, splenomegaly, and 
right renal calculi (Figure 3).
Renal ultrasound reported normal sized kidneys with 
regular morphology, appropriate corticomedullary rela-
tionship with no dilatation of collecting systems. The right 
kidney had a stone of 6.7 mm located at the sinus. Doppler 
perfusion image was normal.
Testicular ultrasound showed both testes and right 
epididymis of normal size, whereas the left epididymis was 
Table 2 Peripheral blood flow cytometry.
Lymphocyte subpopulation
Cells % N
Lymph events — 2,501









Figure 1 Bilateral hilar lymphadenopathy and micronodular 
and diffuse reticular infiltrates.
Figure 2 Osteopenia and bone demineralization.
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enlarged, lobed and with well-defined borders, a size of 
15x7x15 mm and central vascularity on Doppler mode (Fig-
ure 4).
Eye fundoscopy showed temporal and inferior-nasal pe-
riphlebitis which are vascular changes characteristic of 
sarcoidosis (Figure 5). However, fluorescein angiography 
reported a 3/10 excavation in both eyes, central emer-
gency of vessels, attached retinas, and normal choroidal 
phase without alterations in vascular pathways (Figure 6).
Echocardiogram showed an anatomically normal heart, 
left ventricle ejection fraction 72%, shortening fraction 
40%, right ventricle systolic pressure 17 mmHg, diastolic 
interventricular septum 9 mm.
Pulmonary function test results (quality grade A, met 
ATS acceptability and repeatability criteria). Spirometry: 
FEV1 / FVC 89 (102), FVC 2.73 (91%), FEV1 2.43 (93%). Ple-
thysmography: SVC 2.72 (90), IC 1.85 (74), ERV 0.87 (164), 
TGV 1.27 (71), RV 0.40 (45), TLC 3.11 (73) RV/TLC 13 (57), 
compatible with a mild restrictive pattern.
Supraclavicular lymph node biopsy. Hematoxylin-eosin, 
Grocott, Ziehl-Neelsen and PAS staining were performed. 
Histological sections showed loss of lymph node architec-
ture, secondary to the formation of multiple confluent 
noncaseating granulomas (Figure 7), made of numerous 
epithelioid macrophages, giant Langhans cells and other 
cells of foreign body-type. Concentric calcifications or 
Schaumann bodies were observed occasionally (Figure 8) 
as well as asteroid bodies (Figure 9). Neither special stains 
nor PCR nor cultures identified Mycobacterium tuberculo-
sis. Histopathological diagnosis: supraclavicular lymph 
nodes with chronic noncaseating granulomatous lymphad-
enitis compatible with sarcoidosis.
In the early days of hospital stay, the patient had head-
ache and Kernig and Brudzinski signs. Cranial computed 
tomography showed adequate differentiation of gray and 
white matter, normal ventricular system and vascular 
structures without meningeal alterations. Cerebrospinal 
fluid (CSF) was transparent, proteins 30 mg/dl, glucose 49 
mg/dl, leukocytes 1/field. Gram stain and cultures were 
negative. PCR test for Mycobacterium tuberculosis in CSF 
was negative.
Treatment was initiated with prednisone 2 mg/kg/day 
and hydrochlorothiazide 1.2 mg/kg/day. The patient 
showed clinical improvement in his general condition, re-
mission of hepatomegaly and splenomegaly, erythema no-
dosum, as well as disappearance of lymphadenopathy and 
the testicular mass. Mediastinal lymph nodes and pulmo-
nary infiltrates also disappeared (Figure 10).
Figure 3 Retroperitoneal lymphadenopathy and right kidney 
stones.
Figure 4 Testicular ultrasonogram: left epididymis is enlarged in comparison to the right one.
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Figure 7 Lymph node biopsy with non-caseating granulomas.
Figure 8 Lymph node biopsy with Schaumann bodies.
Figure 9 Lymph node biopsy with asteroid bodies.
Figure 10 Lymphadenopathy and pulmonary infiltrates 
remission after treatment.
Figure 5 Fundoscopy: temporal and inferior nasal periphlebitis.
Figure 6 Retinal fluorangiography: normal vessels.
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Four months later, the patient was asymptomatic, had 
recovered 15 kg of weight and had resumed school. In fol-
low up, abdominal tomography showed remission of retro-
peritoneal lymphadenopathy and no evidence of renal 
calculi; spirometry and plethysmography had a normal 
pattern. Laboratory tests showed serum calcium 9.0 mg/
dl, phosphorus 5.8 mg/dl, creatinine 0.8 mg/dl, uric acid 
6.2 mg/dl, 24-hour calciuria 0.93 mg/kg/day, and ACE was 
71 U/l. According to these values, it was considered that 
the sarcoidosis was in remission.
3. Discussion
This case is about an adolescent male with late-onset 
pediatric sarcoidosis who had serious affection of the gen-
eral state leading to cachexia. He also had lung damage, 
hepatomegaly, splenomegaly, adenopathy, erythema no-
dosum and a scrotal mass. The diagnostic approach to pa-
tients with hepatosplenomegaly, allowed to rule out 
several infectious diseases such as tuberculosis, systemic 
mycosis, syphilis, Epstein Barr virus (EBV) and human im-
munodeficiency virus (HIV), as well as infiltrative disor-
ders, such as leukemias, lymphomas, metastatic tumors 
and hemophagocytic lymphohistiocytosis by computed 
tomography, and bone marrow and lymph node biopsies. 
Systemic vasculitis and other autoimmune diseases were 
discarded as well as testicular tumors based on the find-
ings of testicular ultrasound and normal levels of the tu-
mor markers alpha-fetoprotein and beta-gonadotrophin.61
The diagnosis of sarcoidosis was suspected because of 
the presence of a systemic disease with hypercalcemia, 
hypercalciuria and urolithiasis, accompanied by elevated 
levels of ACE and sIL-2R. It was confirmed by histopatho-
logical study of a lymph node which showed the presence 
of multiple noncaseating epithelioid granulomas formed 
by macrophages, giant Langhans cells, asteroid bodies and 
Schaumann bodies. Cytological analysis of bronchoalveolar 
lavage and the Kveim-Siltzbach test could not be per-
formed.
On admission, the patient had chronic respiratory fail-
ure type I (hypoxemia, normocarbia and hyperlactatemia) 
with no cardiovascular repercussion. Chest radiography 
showed diffuse reticular and micronodular infiltrates with 
bilateral hilar lymphadenopathy concordant with the stage 
II of the American Thoracic Society for thoracic sarcoido-
sis classification. Likewise, spirometry and plethysmogra-
phy reported a decrease in FEV1/FVC, compatible with 
mild restrictive lung disease as described in the first two 
stages of pulmonary sarcoidosis, and which normalized af-
ter prednisone treatment.
During his hospital stay, the patient also presented 
headache and meningeal signs which we attributed to sar-
coidosis infiltration of the meninges, since CSF cytochemi-
cal and microbiological studies were normal as well as 
cranial computed tomography. These clinical findings also 
disappeared after prednisone administration.62,63
Although the patient never had ocular manifestations, 
ophthalmological examination was carried out due to the 
high frequency of ocular involvement in sarcoidosis. Pe-
riphlebitis was compatible with uveal sarcoidosis. As pre-
viously described, this is the treatment of choice since 
sarcoidosis eye injuries usually improve rapidly after pred-
nisone administration, preventing disease progression and 
the appearance of other irreversible damage which may 
lead to blindness.64
Hypercalcemia of sarcoidosis traditionally has been at-
tributed to calcitriol production by activated macrophag-
es and monocytes from granulomas, which in turn increase 
the intestinal absorption of calcium and osteoclast activi-
ty with bone resorption and increased levels of serum cal-
cium. However, in this case, the determination of 
calcitriol (1, 25-dihydroxy-vitamin D3) was found to be 
within the reference interval, and suppressed PTH levels; 
this is indicative of inhibition of the parathyroid glands 
due to elevated serum calcium and, on the other hand, 
hypercalcemia was probably caused by another autono-
mous factor such as PTHrP production by activated mac-
rophages, which could not be measured in this case.65
Initially the patient had acute renal failure, but no renal 
replacement therapy was needed. Hypercalcemic hyper-
calciuria with decreased tubular phosphate reabsorption, 
which was expressed as calcium oxalate and calcium phos-
phate, caused him kidney stones. While the acute colic 
pain is uncommon in children with urolithiasis, this patient 
presented right flank pain accompanied by microscopic 
hematuria. As part of the medical management, treat-
ment with hydrochlorothiazide was provided in order to 
reduce the renal calcium excretion and decrease the for-
mation of calcium oxalate and calcium phosphate calculi, 
achieving remission of hypercalciuria and expulsion of re-
nal calculi (Figure 11).66-72
In this patient no studies of histocompatibility antigens 
(HLA) were performed. Regarding immune function, mod-
erate polyclonal hypergammaglobulinemia was observed, 
with appropriate levels of C3 and C4, as described in pa-
tients with sarcoidosis. The phagocytic function tests ni-
troblue tetrazolium slide test and chemiluminescence at 
rest and after stimulus were normal, so the possibility of 
chronic granulomatous disease was discarded.
While flow cytometry on peripheral blood reported a 
total number of lymphocytes within the normal interval, 
Figure 11 Abdominal computed tomography after treatment: 
retroperitoneal lymphadenopathy remission and kidney stone 
disappearance.
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the identification of the major lymphocyte subpopulations 
showed 50.7% of T cells, 33.4% of B lymphocytes and 13.7% 
of NK cells with one CD4/CD8 ratio = 1.22. This could ex-
plain the immune paradox observed in skin tests because 
it was considered that the patient had normal cellular and 
humoral immunity.73-77
Finally, it should be noted that childhood sarcoidosis is 
an underdiagnosed disease in Mexico, so there is no clini-
cal or epidemiological information about this condition in 
our population. This clinical case may contribute to the 
knowledge of sarcoidosis in children whose clinical symp-
toms are nonspecific. In the few reported cases, sarcoido-
sis has been misdiagnosed as juvenile idiopathic arthritis, 
tuberculosis or systemic fungal infections. However, the 
involvement of multiple organs may lead to serious disabil-
ity and/or death, highlighting the importance to consider 
sarcoidosis in the diagnostic approach of patients with 
generalized lymphadenopathy, splenomegaly and hepato-
megaly in order to initiate glucocorticoid therapy, which is 
the most effective treatment to prevent disease and stop 
its progression in most of these patients.
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